• Medicine
  • Published 1996

The Myotoxic Effects of Microencapsulated Naproxen and Carrier Polymer After Intramuscular Injection in Rats

@inproceedings{Bohan1996TheME,
  title={The Myotoxic Effects of Microencapsulated Naproxen and Carrier Polymer After Intramuscular Injection in Rats},
  author={Kevin J Bohan},
  year={1996}
}
Abstract : At the present time ketorolac is the only NSAID approved for intravenous and intramuscular use in humans. The half-life of naproxen is 12-15 hours compared to 4-6 hours for ketoralac, and naproxen has an antipyretic effect. A drug carrier system has been developed which allows for highly lipophilic compounds such as naproxen to be microencapsulated (MEC) for parenteral use. Intramuscular MEC naproxen could provide greater pain relief than ketoralac with a longer duration of action… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

ToradoL IVIIMJOral (Plandex 80000)

  • Syntex Laboratories, Inc.
  • Palo Alto, CA
  • 1995

Implications of am mal welfare on toxicity testing

  • Meyer
  • Human & Experimenttal Toxicology,
  • 1993

Local myotoxicity ofbupivacaine in rabbits after continuous supraclavicular brachia1 plexus block

  • P. Perr, H. Watanare, +3 authors PH
  • Regional Anesthesia,IS,
  • 1993

Extrapolation of safety (i .e., Toxicological data from animals

  • B. Spilker
  • Guide to Clinical Trials (pp. 675-681)
  • 1991
VIEW 2 EXCERPTS

Nonopioid and nonsteroidal analgesic, antipyretic, and anti-inflammatory drugs

  • R. K. Stoelting
  • Stoelting, R.K. (Ed.), Pharmacology & Physiology on Anesthetic Practice (2nd ed.) (pp.252-263). Philadelphia: J.B. Lippincott Company.
  • 1991
VIEW 1 EXCERPT

Opiod agonists and antagonists

  • RK.
  • Stoelting, RK (Ed.). Pharmacology
  • 1991